These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18081375)

  • 1. Parnaparin : a review of its use in the management of venous thromboembolism, chronic venous disease and other vascular disorders.
    McKeage K; Keating GM
    Drugs; 2008; 68(1):105-22. PubMed ID: 18081375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on the clinical use of the low-molecular-weight heparin, parnaparin.
    Camporese G; Bernardi E; Noventa F
    Vasc Health Risk Manag; 2009; 5():819-31. PubMed ID: 19851520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of unfractionated heparin and a low-molecular-weight heparin following thrombolytic therapy for acute ST-segment elevation myocardial infarction.
    Wang XK; Zhang Y; Yang CM; Wang Y; Liu GY
    Clin Drug Investig; 2006; 26(6):341-9. PubMed ID: 17163268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical use of parnaparin in major and minor orthopedic surgery: a review.
    Bugamelli S; Zangheri E; Montebugnoli M; Guerra L
    Vasc Health Risk Manag; 2008; 4(5):983-90. PubMed ID: 19183746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum).
    Cosmi B; Filippini M; Tonti D; Avruscio G; Ghirarduzzi A; Bucherini E; Camporese G; Imberti D; Palareti G;
    J Thromb Haemost; 2012 Jun; 10(6):1026-35. PubMed ID: 22487001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjunctive low molecular weight heparin during fibrinolytic therapy in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials.
    Singh S; Bahekar A; Molnar J; Khosla S; Arora R
    Clin Cardiol; 2009 Jul; 32(7):358-64. PubMed ID: 19609890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism.
    Robertson L; Strachan J
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD006771. PubMed ID: 28195640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Unfractionated heparin and low molecular weight heparin for acute coronary syndromes--assessment of a Cochrane review].
    Husted SE; Nielsen HK
    Ugeskr Laeger; 2010 Sep; 172(37):2522-6. PubMed ID: 20836961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Bates SM; Greer IA; Pabinger I; Sofaer S; Hirsh J
    Chest; 2008 Jun; 133(6 Suppl):844S-886S. PubMed ID: 18574280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes.
    Magee KD; Sevcik W; Moher D; Rowe BH
    Cochrane Database Syst Rev; 2003; (1):CD002132. PubMed ID: 12535430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parnaparin. A review of its pharmacology, and clinical application in the prevention and treatment of thromboembolic and other vascular disorders.
    Frampton JE; Faulds D
    Drugs; 1994 Apr; 47(4):652-76. PubMed ID: 7516862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-molecular weight heparins in venous and arterial thrombotic disease.
    Bijsterveld NR; Hettiarachchi R; Peters R; Prins MH; Levi M; Büller HR
    Thromb Haemost; 1999 Sep; 82 Suppl 1():139-47. PubMed ID: 10695506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
    PRIME CARE Study Investigators Group
    Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of low molecular weight heparin with unfractionated heparin during percutaneous coronary interventions: a meta-analysis.
    Kodumuri V; Adigopula S; Singh P; Swaminathan P; Arora R; Khosla S
    Am J Ther; 2011 May; 18(3):180-9. PubMed ID: 20027109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
    Hirsh J; Raschke R
    Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of anticoagulants in ST-segment elevation myocardial infarction patients; a focus on low-molecular-weight heparin.
    Gurm HS; Eagle KA
    Cardiovasc Drugs Ther; 2008 Feb; 22(1):59-69. PubMed ID: 18165932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Heparins].
    Marbet GA
    Ther Umsch; 2003 Jan; 60(1):10-3. PubMed ID: 12638471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspectives on antithrombotic agents: from unfractionated heparin to new antithrombotics.
    Agnelli G; Sonaglia F
    Haematologica; 2002 Jul; 87(7):757-70. PubMed ID: 12091128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.